This month Mike McCurdy rejoins the podcast to discuss the ATHOS-3 trial. Mike was one of the co-authors on this impressive publication and gives us insight into the study and its results. Very thought provoking!
You can get CME credit for this episode here! Click here for CME Account Creation Instructions
Up to one-third of patients with status epilepticus will not respond to benzodiazepines. Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied. The...
Bryan Hayes rejoins the podcast to discuss some great pearls and pitfalls with select medications used to resuscitate and treat critically ill patients. This...
ICH accounts for approximately 15 percent of all strokes. Despite improvements in neurocritical care, the mortality for patients with ICH can still reach 50...